Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 11, 2008, Pages 1255-1257

  Kuwabara, Satoshi ^a   Misawa, S ^a   Kanai, K ^a   Sawai, S ^a   Hattori, T ^a   Nishimura, M ^a   Nakaseko, C ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; THALIDOMIDE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; ASCITES; BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; NERVE CONDUCTION; NEUROLOGIC DISEASE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; POEMS SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; BLOOD; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; POEMS SYNDROME; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55249116538     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.150177     Document Type: Article

References (16)

1. Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 1980;59:311-22.
2. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 112 cases in Japan. Neurology 1984;34:712-20.
3. Miralles GD, O'Fallon JR, Talley NJ. Plasma cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992;327:1919-23.
4. Dispenzieri A, Kyle R, Lacy MQ, et al. POEMS syndrome: definitions and long-term prognosis. Blood 2003;101:2496-506.
5. Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996;347:702.
6. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998;21:1390-7.
7. Dispenzieri A. POEMS syndrome. Blood Rev 2007;21:285-99.
8. Jaccard A, Royer B, Brouel JC, et al. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 2002;99:3057-9.
9. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004;104:3400-7.
10. Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006;66:105-7.
11. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;1:16-9.
12. Sinisalo M, Hietaharju A, Sauranen J, et al. Thalidomide in POEMS syndrome: case report. Am J Hematol 2004;76:66-8.
13. Kim SY, Lee SA, Ryoo HM, et al. Thalidomide for POEMS syndrome. Ann Hematol 2006;85:545-6.
14. Apfel SC, Zochodne DW. Thalidomide neuropathy: too much or too long? Neurology 2004;62:2158-9.
15. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007;110:1075-6.
16. Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42.